Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous trastuzumab + pertuzumab neoadjuvant therapy for non-metastatic HER2-positive breast cancer in Algerian women
PACTR202608692744020Phase 4Completed
- Sponsor
- Laboratoire de Recherche en Cancérologie
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of trastuzumab and pertuzumab in breast cancer, sponsored by Laboratoire de Recherche en Cancérologie. Primary endpoint: Pathological complete response rate. Started Dec 2024; status: completed.
02
Drugs
trastuzumabpertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on PACTR202608692744020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202608692744020.